HireQuest (HQI) Q4 2025 Earnings Transcript

HireQuest reported Q4 revenue of $7.0 million, down 13% year over year, with full-year revenue declining to $30.6 million and system-wide sales falling 11.3% to $500.2 million. Offsetting the top-line decline, adjusted net income was flat at $2.7 million in Q4 and $10.0 million for the year, working capital rose to $33 million, and the company ended 2025 debt-free with $40.3 million of availability. Management also authorized a $20 million share repurchase program and reiterated a $0.06 quarterly dividend, while highlighting MRI restructuring and a cautiously improving staffing environment.

Analysis

HQI is increasingly a capital-return story wrapped around a cyclical staffing franchise. The key read-through is not the modest revenue compression itself, but that the business is now showing operating leverage on the downside: debt is gone, workers’ comp has normalized, and adjusted earnings held despite a weaker top line. That combination gives management real optionality to keep dividends and buybacks in place even if the macro backdrop remains only “stable,” which should support valuation on the downside.

The MRI restructuring is the bigger second-order variable. By stripping out the lower-quality permanent-placement exposure and retaining the contract staffing piece plus a minority interest, HQI is effectively de-risking reported growth but also reducing the probability of another earnings disappointment tied to a slow, lumpy segment. Near term, headline revenue will likely look worse on a year-over-year basis, but the market may be underestimating how much of the prior drag was margin-neutral noise rather than value destruction; that can create a cleaner compare into the second half if labor demand keeps normalizing.

The buyback authorization matters because the stock can now be a self-funded return story while the business is still conservatively financed. If the shares trade at a low-teens multiple of normalized adjusted earnings, repurchases compete directly with acquisitions that management itself is describing as scarce and lower quality, which raises the odds of capital being recycled into stock rather than forced deal-making. The main risk is that “stabilization” turns out to be a plateau at a lower activity level, in which case earnings are likely range-bound for 2-3 quarters and the dividend/buyback combo only partially offsets multiple compression.

Consensus appears to be focusing on the revenue decline and missing the asymmetry in cash deployment and balance sheet repair. In a weak hiring tape, HQI’s franchise model should lag pure volume inflections but outperform on cash conversion, so the right expression is not a fast-growth trade; it is a defensive compounder with optionality on a labor-cycle bottom. If office-level survey trends translate into even modest sequential improvement in Q2/Q3, the stock could rerate quickly because expectations are already anchored to a low-growth reset.

Key Decisions for Investors

• Long HQI on a 3-6 month horizon as a capital-return compounder; target a re-rating if normalized adjusted EPS stability persists and buybacks begin to reduce share count. Use a tight stop if sequential royalties fail to improve by mid-year.
• Sell cash-secured puts on HQI with strikes 10-15% below spot for the next two quarters; the dividend plus buyback creates a favorable carry profile while waiting for a better entry.
• Pair long HQI / short a more cyclically exposed staffing name (e.g., MAN or RHI) for a 2-quarter horizon to isolate the benefit of balance-sheet repair and capital return versus pure labor-beta exposure.
• Avoid chasing the stock on the buyback headline alone; add only on a post-earnings pullback if management signals repurchases are being executed rather than merely authorized.
• If Q2 system-wide sales inflect positively, consider upside call spreads in HQI for the next 4-6 months; the setup offers asymmetric upside from a low base, but the thesis breaks if labor demand remains flat-to-down.